1-β-arabinofuranosylcytosine in therapy of leukemia: Preclinical and clinical overview

Pharmacology and Therapeutics

Volumn 56, Issue 3, 1992, Pages 307-321

  Rustum, Youcef M ^a   Raymakers, Reiner A ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; ASPARAGINASE; CYTARABINE; DRUG METABOLITE; IDARUBICIN; MITOMYCIN C;

ANIMAL EXPERIMENT; BONE MARROW SUPPRESSION; CONJUNCTIVITIS; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; FEVER; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA; MALE; MOUSE; NAUSEA; PRIORITY JOURNAL; REVIEW; SEPTICEMIA; VOMITING;

ANIMAL; CLINICAL TRIALS; CYTARABINE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMAN; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0027095868     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(92)90022-R     Document Type: Review

References (70)

1. Sequential combination of systemic high dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma
2. Amsacrine with high-dose cytarabine is highly effective for refractory and relapsed acute lymphoblastic leukemia in adults
3. The clinical use of cytogenetics in acute leukemia
4. The clinical significance of biological characteristics of the cells in acute myeloid leukemia
5. Cytarabine and neurologic toxicity
6. High-dose cytosine arabinoside in the initial treatment of acute leukemia
7. Toxicity of high-dose Ara-C in children and adolescents
8. Peripheral neuropathy associated with high-dose Ara-C therapy
9. Clinical results and pharmacokinetics of high-dose cytosine arabinoside (HD ara-C)
10. Sequential high-dose Ara-C and asparaginase vs high-dose Ara-C alone in the treatment of patients with relapsed and refractory acute leukemia
11. Treatment of poor risk acute leukemia with sequential high-dose Ara-C and asparaginase
12. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapse acute myelogenous leukemia—A cancer and leukemia group B study
13. Adult acute nonlymphocytic leukemia
14. Allogeneic bone marrow transplantation versus intensification chemotherapy for acute myelogenous leukemia in first remission: a prospective controlled trial
15. The association between high-dose cytarabine neurotoxicity and renal insufficiency
16. Cerebellar toxicity following high-dose cytosine arabinoside
17. A pilot study of high dose 1-β-d-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: clinical response and pharmacology
18. Continuous infusion of high-dose cytosine arabinoside without anthracyclines as induction and intensification therapy in adults under age 50 with newly diagnosed acute myelogenous leukemia
19. Intensive chemotherapy is the treatment of choice for elderly patients with acute myelogenous leukemia
20. Successful treatment of meningeal leukemia using systemic high-dose cytosine arabioside
21. Drug-induced toxicities associated with high-dose cytosine arabinoside infusions
22. Central nervous system toxicity of high-dose cytosine arabinoside
23. High-dose cytosine arabinoside therapy for refractory leukemia
24. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission induction of acute nonlymphoblastic leukemia
25. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myelold and lymphoblastic leukemia
26. High-dose cytosine arabinoside and mAMSA induction and consolidation in patients with previously untreated de novo acute nonlymphoblastic leukemia: phase I pilot study for the Eastern Cooperative Oncology Group
27. Prolonged survival after high-dose cytosine arabinoside and amsacrine induction in patients with previously untreated de novo acute nonlymphoblastic leukemia
28. Distribution of kinase and deaminase of 1-β-d-arabinofurano-sylcytosine in tissues of man and mouse
29. Attenuated high-dose cytosine arabinoside in the treatment of the elderly patient with acute nonlymphocytic leukemia
30. Phase I–II clinical and pharmacological studies of high-dose cytosine arabinoside in refractory leukemia
31. Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia
32. A four term experience with anthracycline, cytosine arabinoside, vincristine and prednisone combination chemotherapy in 325 adults with acute leukemia
33. Short remission durations in therapy-related leukemia despite cytogenetic complete responses to high-dose cytarabine
34. High-dose cytosine arabinoside and daunorubicin as primary therapy in elderly patients with acute myelogenous leukemia
35. A model for the chemotherapy of acute leukemia with 1-β-furanosylcytosine
36. Systemic high-dose ara-C for the treatment of meningeal leukemia In adult acute lymphoblastic leukemia and non-Hodgkin's lymphoma
37. Neurotoxicity associated with systemic high-dose cytosine arabinoside
38. Intermediate and high-dose cytosine arabinoside-containing regimens for induction and consolidation therapy for patients with acute lymphoblastic leukemia and lymphoblastic nonHodgkin's lymphoma: the leyden experience and review of the literature
39. Side effects of intermediate- and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute leukemia and nonHodgkin's
40. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukemia
41. High-dose ara-C (HiDAC) plus asparaginase in elderly patients with acute nonlymphocytic leukemia; a pilot multicentric study by the Italian Cooperative Group GIMEMA
42. Empire antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
43. Pharmacologically directed araC therapy for refractory leukemia
44. Peripheral neuropathy after high-dose cytosine arabinoside, daunorubicln and asparaginase consolidation for acute nonlymphocytlc leukemia
45. Ara-C syndrome during low-dose continuous infusion therapy
46. Abrogation of the prognostic significance of low leukemic cell retention of cytosine arabinoside triphosphate by intensification of therapy and by alteration in the dose and schedule of administration of cytosine arabinoside
47. Prediction of response of acute nonlymphocytic leukemia to therapy with ‘high dose’ cytosine arabinoside
48. Acute myeloblastic leukemia in elderly patients. Treatment and prognostic factors
49. Pharmacokinetics and cellular determinants of response to 1-β-arabinosylcytosine (AraC)
50. High-dose cytosine arabinoside; response to therapy in acute leukemia and non-Hodgkin's lymphoma
51. High dose cytosine arabinoside (HDARAC) in refractory acute leukemia
52. Neuropathy due to cytosine arabinoside
53. Metabolism and intracellular retention of 1-β-d-arabino-furanosylcytosine as predictors of response of animal tumors
54. Correlation between leukemic cell retention of 1-β-d-arabinofuranosylcytosine 5′-triphosphate and response to therapy
55. Pharmacokinetic parameters of 1–6-d-arabinofuranosylcytosine (ara-C) and their relationship to intracellular metabolism of ara-C, toxicity, and response of patients with acute nonlymphocytic leukemia treated with conventional and high-dose ara-C
56. Effect of dose and schedule of pharmacokinetics of high dose cytosine arabinoside in plasma and cerebrospinal fluid
57. Reinduction therapy for advanced refractory acute lymphoblastic leukemia of childhood
58. The toxicity of cytarabine
59. Cytidine deaminase and the development of resistance of human acute leukemia cells to cytosine arabinoside
60. Cytosine arabinoside for induction, salvage and consolidation therapy for adult acute lymphoclastic leukemia
61. High-dose cytosine arabinoside in the consolidation therapy of acute nonlymphoblastic leukemia in remission
62. Evaluation of intensive postremission chemotherapy for adults with acute nonlymphocytic leukemia using high-dose cytosine arabinoside with l-asparaginase and amsacrine with etoposide
63. Does the metabolite uracil arabinoside inhibit cytosine arabinoside (Ara-C) penetration into the cerebrospinal fluid during high-dose Ara-C therapy?
64. Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia
65. Sequential high-dose cytosine arabinoside asparaginase treatment in advanced childhood leukemia
66. Intermediate and high dose Ara-C and m-AMSA for remission induction and consolidation treatment of patients with acute myeloid leukemia: an EORTC leukemia cooperative group phase II study
67. High-dose cytarabine and daunorubicin as consolidation therapy for acute myeloid leukemia in first remission: long-term follow-up and results
68. Amsacrine with high-dose cytarabine in acute leukemia
69. Modulation of cytosine arabinoside (Ara-C) and high-dose Ara-C in acute leukemia
70. Modulation of 1-β-d-arabinofuranosylcytosine metabolism by thymidine in human acute leukemia